Dr Shadman discusses an indirect comparison evaluating zanubrutinib vs acalabrutinib plus venetoclax in chronic lymphocytic leukemia.
Assessing Zanubrutinib vs Acalabrutinib Plus Venetoclax in Frontline CLL
In a post hoc indirect comparison, data showed zanubrutinib was linked to improved PFS vs acalabrutinib/venetoclax in patients with treatment-naive CLL.
Mazyar Shadman, MD, MPH, discusses a post hoc analysis that compared data BTK inhibitor–based regimens for treatment-naive chronic lymphocytic leukemia.
Trending on OncLive
1
FDA Approves Zidesamtinib in Pretreated ROS1+ NSCLC
2
Ivonescimab Plus Chemotherapy Sustains OS Benefit Across Western and Asian Patients in Pretreated EGFR-Mutated NSCLC
3
Sacituzumab Govitecan Yields Responses in Platinum-Resistant Ovarian Cancer
4
How Are Treatment Intensification and Sequencing Reshaping Care in Prostate Cancer and RCC
5